EP Patent

EP3662912A1 — Improved dosages of eteplirsen for treating duchenne muscular dystrophy

Assigned to Sarepta Therapeutics Inc · Expires 2020-06-10 · 6y expired

What this patent protects

Improved compositions and methods for treating muscular dystrophy by administering antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping are described.

USPTO Abstract

Improved compositions and methods for treating muscular dystrophy by administering antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping are described.

Drugs covered by this patent

Patent Metadata

Patent number
EP3662912A1
Jurisdiction
EP
Classification
—
Expires
2020-06-10
Drug substance claim
No
Drug product claim
No
Assignee
Sarepta Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.